Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
12/2003
12/23/2003US6667061 Microparticles comprising polymeric binder and injection vehicle, wherein microparticles are suspended in vehicle at concentration of greater than 30 mg/ml to form suspension having viscosity of 600 cp at 20 degrees C
12/23/2003US6667060 Pregelatinized starch in a controlled release formulation
12/23/2003US6667059 Odor-masking coating for a pharmaceutical preparation
12/23/2003US6667058 Oral forms of administration containing solid flupirtine with controlled release of active substance
12/23/2003US6667057 At least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours.
12/23/2003US6667056 Tablet comprising: the active ingredient; an acid and an alkali such as sodium glycine carbonate manufactured by direct compression in normal thermohygrometric conditions and with standard tabletting equipment
12/23/2003US6667055 Filler binder for tablets
12/23/2003US6667054 Metformin hydrochloride tablets
12/23/2003US6667053 D and L etherlipid stereoisomers and liposomes
12/23/2003US6667052 Drug delivery; diabete therapy; penetration enhancer mixture of protein and oxidizer
12/23/2003US6667050 Chewable oral contraceptive
12/23/2003US6667048 Pharmaceutical composition comprising taxoid, taxane or taxine as chemotherapeutic agent, alpha-tocopherol, tocopherol polyethylene glycol succinate, and aqueous phase, in form of emulsion or microemulsion with drug in oil phase
12/23/2003US6667042 Ciprofloxacin administered in three dosages forms with different release profiles; Cmax is reached in < about twelve hours
12/23/2003US6667041 Use of neurotoxin therapy for treatment of urologic and related disorders
12/23/2003US6667026 Allergic contact dermatitis treatment and composition therefor
12/23/2003CA2323211C Topical anesthetic formulation
12/23/2003CA2302232C Ophthalmic composition including a cationic glycoside and an anionic therapeutic agent
12/23/2003CA2294251C Satiety product
12/23/2003CA2289668C Flow controller configurations for an active agent delivery device
12/23/2003CA2269505C Cleansing products
12/23/2003CA2264394C Use of bilayer forming emulsifiers in nutritional compositions comprising divalent metal salts
12/23/2003CA2223643C Sustained-release formulation of d-threo-methylphenidate
12/23/2003CA2219584C Method of granulating powder and apparatus for it
12/23/2003CA2147172C Transdermal therapeutic system for the release of 17-.beta.-estradiol and process for its production
12/18/2003WO2003104402A2 Non-polymeric hematopoietic cell clots for delivery of active agents
12/18/2003WO2003104303A1 Polyaminoacids functionalized by alpha tocopherol and uses thereof, particular for therapeutic applications
12/18/2003WO2003104283A2 Polymeric surfactant compositions and methods of manufacture and use
12/18/2003WO2003104260A2 Pharmaceutical formulation
12/18/2003WO2003104192A2 Controlled release formulation of lamotrigine
12/18/2003WO2003103822A2 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
12/18/2003WO2003103714A1 Stabilised pharmaceutical compositions on the basis of polyoxyethylated castor oil and method for manufacturing the same
12/18/2003WO2003103713A1 Rapidly disintegrating tablet and process for producing the same
12/18/2003WO2003103691A1 Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions
12/18/2003WO2003103687A1 Liquid formulation of decitabine and use of the same
12/18/2003WO2003103674A1 Tablets comprising ciprofloxacin hydrochloride
12/18/2003WO2003103673A1 Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein
12/18/2003WO2003103643A1 Oral antidepressant formulation comprising a selective serotonin_reuptake inhibitor
12/18/2003WO2003103642A1 Solubilisation of drugs in hfa propellant by means of emulsions
12/18/2003WO2003103641A1 Patch
12/18/2003WO2003103640A1 Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
12/18/2003WO2003103639A1 Chewable soft capsule
12/18/2003WO2003103638A1 Stabilized pharmaceutical compositions containing benzimidazole compounds
12/18/2003WO2003103637A2 Modified release, multiple unit drug delivery systems
12/18/2003WO2003103636A1 A novel drug dosing regimen
12/18/2003WO2003103635A1 Extended release formulation of divalproex sodium
12/18/2003WO2003103634A1 Sustained release oral dosage forms of gabapentin
12/18/2003WO2003103633A1 Nanoparticulate sterol formulations and sterol combinations
12/18/2003WO2003103632A1 Nanoparticulate polycosanol formulations and novel polycosanol combinations
12/18/2003WO2003103631A1 Novel high viscosity embolizing compositions comprising prepolymers
12/18/2003WO2003103630A1 Liposomal vitamin a and method of preparation
12/18/2003WO2003103629A1 Orally disintegrating tablets and process for obtaining them.
12/18/2003WO2003103628A1 Device against diabetes (dicodia)
12/18/2003WO2003103624A1 Method and composition for improving sensory characteristics of semisolid predominantly anhydrous
12/18/2003WO2003103603A2 Novel formate salt of o-desmethyl-venlafaxine
12/18/2003WO2003103596A2 Stabilized nanoparticle formulations of camptotheca derivatives
12/18/2003WO2003103594A2 Micelle assemblies
12/18/2003WO2003103588A2 Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer
12/18/2003WO2003103585A2 Methods of treating angiogenesis, tumor growth, and metastasis
12/18/2003WO2003103582A2 Reduction of gelatin cross-linking
12/18/2003WO2003103581A2 Compositions and methods for liver growth and liver protection
12/18/2003WO2003103576A2 Reconstitutable compositions of biodegradable block copolymers
12/18/2003WO2003103549A1 Ophthalmic drug delivery system
12/18/2003WO2003103475A2 Prevention and reduction of blood loss
12/18/2003WO2003103389A2 Cryopreservation of haptenized tumor cells
12/18/2003WO2003086267A3 Multi-phase, multi-compartment capsular system
12/18/2003WO2003082302A3 Bioadhesive directed somatic cell therapy
12/18/2003WO2003082242A3 Highly aqueous liquid carrier formulations
12/18/2003WO2003079991A3 Method for administration of growth hormone via pulmonary delivery
12/18/2003WO2003074474A3 Multiple-component solid phases containing at least one active pharmaceutical ingredient
12/18/2003WO2003074027A3 Self emulsifying drug delivery systems for poorly soluble drugs
12/18/2003WO2003071986A3 Method for treating otic disorders
12/18/2003WO2003068246A3 Improvements in or relating to compositions
12/18/2003WO2003061633B1 Non-gelatin capsule shell formulation comprising iota-carrageenan and kappa-carrageenan
12/18/2003WO2003059329A3 Polytartrate composition
12/18/2003WO2003057135A3 Aqueous compositions containing metronidazole
12/18/2003WO2003057128A3 Lipid particles and suspensions and uses thereof
12/18/2003WO2003053431A3 Pharmaceutical compositions based on azetidine derivatives
12/18/2003WO2003053417A3 Method for making a tablet comprising a morphine type analgesic and resulting tablet
12/18/2003WO2003051281A3 Composition and method to treat viral bacterial and parasitic infections and infestations
12/18/2003WO2003048298A3 Nanoparticles containing polymeric nucleic acid homologs, pharmaceutical compositions and articles of manufacture containing same and methods of use thereof
12/18/2003WO2003047503A3 Delivery of medicaments to the nail
12/18/2003WO2003045330A3 Materials and methods for making improved micelle compositions
12/18/2003WO2003044080A8 Water-in-silicone emulsions
12/18/2003WO2003039677A3 Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
12/18/2003WO2003039444B1 Topical use of cytokines and/or chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases
12/18/2003WO2003024297A3 Cell storage and delivery system
12/18/2003WO2003022303A3 Use of hcg and lh in controlled ovarian hyperstimulation
12/18/2003WO2003022302A3 USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
12/18/2003WO2003009817B1 Stable lyophilized pharmaceutical formulation of igg antibodies
12/18/2003WO2003006045A3 Cxcl10 treatment of secondary tissue degeneration
12/18/2003WO2003000228A3 Method for high through put screening using a small scale mill or microfluidics
12/18/2003WO2002067916A3 Pharmaceutical salts
12/18/2003WO2002066668A3 Method for producing proteins by fermentation of microorganisms from the thermus family, the protein mixture thus obtained and cosmetic compositions containing same
12/18/2003WO2002058582A3 Anti-carious candies and confections
12/18/2003WO2002041883A3 As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation
12/18/2003WO2002017878A8 Lung surfactant compositions with dynamic swelling behaviour
12/18/2003US20030232905 Pressure sensitive adhesive compositions
12/18/2003US20030232895 Mixing ethylenically-unsaturated monomer and multi-olefinic crosslinking agent; subjecting to polymerization conditions and foaming to form composite; combining at least one strengthening agent
12/18/2003US20030232892 Microcrystalline zeaxanthin with high bioavailability in oily carrier formulations
12/18/2003US20030232881 Large crystals suitable for use in direct compression
1 ... 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 ... 2991